-
Medical journals
- Career
Recommendation of the Society for Transfusion Medicine No. 20 Cold red blood cell antibodies testing before cardiothoracic surgery on cardiopulmonary bypass
Authors: M. Králová 1; J. Masopust 2; M. Písačka 3; V. Řeháček 4; P. Turek 5
Authors‘ workplace: Ústav hematologie a krevní transfuze, Praha 1; Transfuzní oddělení, Krajská zdravotní, a. s. – Masarykova nemocnice v Ústí nad Labem, o. z. 2; Ústav hematologie a krevní transfuze, Praha 3; Transfuzní oddělení, FN Hradec Králové 4; Transfúzní oddělení, Fakultní Thomayerova nemocnice, Praha 5
Published in: Transfuze Hematol. dnes,32, 2026, No. 1, p. 65-66.
Category: Best Practices
doi: https://doi.org/10.48095/cctahd202601Overview
Cold red blood cell antibodies are usually clinically insignificant. However, they may have an adverse clinical impact in patients undergoing cardiac surgery with the use of cardiopulmonary bypass with cooling of the patient‘s blood. We present consensus recommendation for the screening and titration of cold red blood cell antibodies in these patients.
Keywords:
cardiac surgery – Cardiopulmonary bypass – cold RBC antibodies
Sources
1. Jalink M, Yan MTS, Cohn CS, et al. Systematic review for serological testing for cold agglutinins: The BEST collaborative study. Transfusion. 2024; 64 : 1331–1349.
2. Sapatnekar S, Figueroa PI. Cold antibodies in cardiovascular surgery. Is preoperative screening necessary? Am J Clin Pathol. 2016; 145 : 789–795.
3. Masopust J, Písačka M. AIHA s chladovými protilátkami. In: Praktická imunohematologie – erytrocyty (2. přepracované vydání). Grada Publishing 2022.
4. Nancy L, Van Buren MD. Cold Agglutinin Disease. In: Transfusion Medicine and Hemostasis (3rd ed.) 2019.
5. Foroughi M, Majidi M, Hekmat M, Beheshti M. What the cardiac surgeons have to know about cold agglutination management. Egypt J Cardiothor Anesth. 2014; 8 : 101–103.
6. Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood. 2013; 122 (7): 1114–1121.
Do redakce doručeno dne: 7. 11. 2025.
Přijato do tisku dne: 11. 11. 2025.
MUDr. Jiří Masopust
Transfuzní oddělení KZ, a. s., Masarykova nemocnice v Ústí nad Labem, o.z.
Sociální péče 3316/12A
401 13 Ústí nad Labem
e-mail: jiri.masopust@kzcr.eu
Labels
Haematology Internal medicine Clinical oncology
Article was published inTransfusion and Haematology Today
2026 Issue 1-
All articles in this issue
- Venetoklax – základ neintenzivní cílené léčby akutní myeloidní leukémie
- Acute myeloid leukaemia – how the approach to diagnosis, risk stratification, and treatment options has changed
- Venetoclax plus azacitidine as a bridge treatment to allogeneic stem cell transplantation in acute myeloid leukaemia patients
- What can be expected from venetoclax + azacitidine (VEN+AZA) in acute myeloid leukaemia (AML) – results from VIALE-A and post-hoc analyses
- Antifungal prophylaxis in patients with acute myeloid leukaemia treated with venetoclax and azacitidine
- Treatment of multiple myeloma with manifestations of light chain deposition disease; complete remission with minimal residual disease negativity following treatment with daratumumab, dexamethasone, and lenalidomide – a case report and a review of the literature
- Concurrent occurrence of BCR:: ABL1-positive chronic myeloid leukaemia and Philadelphia-negative myeloproliferative neoplasm
- Principles of Rational Haemotherapy Interdisciplinary Consensus Statement
- Recommendation of the Society for Transfusion Medicine No. 20 Cold red blood cell antibodies testing before cardiothoracic surgery on cardiopulmonary bypass
- 18. Střešovický transfuzní den
- Zanubrutinib čtyřikrát jinak v klinické praxi
- Hodgkinův lymfom – klíčová sdělení z ASH 2025
- Transfusion and Haematology Today
- Journal archive
- Current issue
- Online only
- About the journal
Most read in this issue- Principles of Rational Haemotherapy Interdisciplinary Consensus Statement
- Treatment of multiple myeloma with manifestations of light chain deposition disease; complete remission with minimal residual disease negativity following treatment with daratumumab, dexamethasone, and lenalidomide – a case report and a review of the literature
- What can be expected from venetoclax + azacitidine (VEN+AZA) in acute myeloid leukaemia (AML) – results from VIALE-A and post-hoc analyses
- Acute myeloid leukaemia – how the approach to diagnosis, risk stratification, and treatment options has changed
Login#ADS_BOTTOM_SCRIPTS#Forgotten passwordEnter the email address that you registered with. We will send you instructions on how to set a new password.
- Career